v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
Column | Value |
---|---|
Trial registration number | ISRCTN85874083 |
Full text link
Last imported at : Sept. 1, 2021, 11 p.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
First author
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
Contact
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
rehan.quadery@nhs.net |
Registration date
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
2021-02-09 |
Recruitment status
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Recruiting |
Study design
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
RCT |
Allocation
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Randomized |
Design
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Parallel |
Masking
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Not reported |
Center
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
single-center |
Study aim
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Treatment |
Inclusion criteria
Last imported at : May 20, 2021, 7:59 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Current inclusion criteria as of 13/05/2021: 1. Adult male or female individuals, age =18 years and =65 years 2. Patients giving written informed consent to participate in the study (ie GCS 15/15: conscious,Alert and oriented 3. COVID-19 documented by a positive RT-PCR test/Rapid Antigen Test 4. Hospitalised patients with severe COVID-19,requiring supplemental oxygen through non-re-Breath mask between 10 - 15L/min maintaining saturations between92-96% for up to 30 hours and between 94 - 98% for 1st six hours 5. Clinical/radiological evidence of interstitial pneumonia requiring admission(optional) _____ Previous inclusion criteria: 1. Aged between 18 and 65 years 2. COVID-19 infection documented by a positive RT-PCR test 3. Hospitalised with severe COVID-19 infection, characterized by fever (at the time of screening or when admitted) and requiring supplemental oxygen through non-rebreather mask between 10 and 15 l/ min 4. Clinical/radiological evidence of interstitial pneumonia requiring admission (optional) 5. Informed written consent given |
Exclusion criteria
Last imported at : May 20, 2021, 7:59 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Current exclusion criteria as of 13/05/2021: 1. Patients who require invasive or non-invasive (including CPAP and high flow nasal cannula). ventilation at the time of inclusion 2. AST/ALT values >5 fold the upper normal limit 3. Impairment of renal function( creatinine clearance<30ml/min/m²) 4. Absolute neutrophil count below 500 cells/mm³ 5. Absolute platelet count below 50,000 cells/mm³ 6. Documented sepsis or high clinical suspicion of superimposed severe bacterial or fungal infection 7. Concomitant acute medical emergencies, such as AMI, acute pericarditis, PE, stroke, acute Surgical and orthopaedic emergencies like acute abdomen and fractured neck of femur etc. 8. Comobidities or concomitant medications likely to be incompatible for cotrimoxazole use pregnancy or lactation 9. History of cotrimoxazole hypersensitivity 10. Patients participating in another clinical trial for SARS-CoV-2 infection _____ Previous exclusion criteria: 1. Require invasive or non-invasive (including CPAP and high flow nasal cannula) ventilation at the time of inclusion 2. Aspartate transaminase (AST)/alanine transaminase (ALT) ratio >5 times the ULN 3. Documented impairment of renal function 4. Absolute neutrophil count <500 cells/mm³ 5. Absolute platelet count <50,000 cells/mm³ 6. Documented sepsis or high suspicion of superimposed severe bacterial or fungal infection 7. Comorbidities or concomitant medications likely to be incompatible for cotrimoxazole use 8. Pregnancy or lactation 9. History of cotrimoxazole hypersensitivity 10. Participating in another clinical trial for SARS-CoV-2 infection |
Number of arms
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
2 |
Funding
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
School of Tropical Medicine; Kolkata |
Inclusion age min
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
18 |
Inclusion age max
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
65 |
Countries
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
India |
Type of patients
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Moderate disease at enrollment |
Severity scale
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
3: Moderate disease at enrollment |
Total sample size
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
200 |
primary outcome
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
1.Clinical status; the number of patients requiring escalation of care to non-invasive ventilation (CPAP and HFNC) and invasive ventilation measured using the 7-point ordinal scale (scored from 1 to 7 as follows: 1= death; 2= hospitalised; requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3= hospitalised; requiring non-invasive ventilation or high flow oxygen devices; 4= hospitalised; requiring supplemental oxygen; 5= hospitalised; not requiring supplemental oxygen; but in need of ongoing medical care (COVID-19 related or otherwise); 6= hospitalised; not requiring supplemental oxygen and no longer requires ongoing medical care (independent); or 7= not hospitalised) between baseline and hospital discharge or death 2. Duration of hospitalisation measured from patient records between baseline and hospital discharge or death 3. Number of in-patient deaths measured from patient records between baseline and hospital discharge or death |
Notes
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
|
Phase
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
Not reported |
Arms
Last imported at : Feb. 19, 2021, 12:45 a.m. Source : International Clinical Trials Registry Platform (ICTRP) |
[{"arm_notes": "", "treatment_id": 331, "treatment_name": "Cotrimoxazole", "treatment_type": "Antibiotics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}] |